Tag: Monotherapy
ADC Therapeutics Administers First Patient Dose in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as Monotherapy and in Combination with Gemcitabine in Advanced Solid Tumors
ADCT-601 binds to AXL, a cancer antigen expressed in solid tumors such as sarcomas and associated with resistance to chemotherapy ADCT-601 has been observed to exhibit a manageable safety profile…